FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives

The Food and Drug Administration has approved a new pancreatic cancer drug that nearly doubled patients’ average survival times for one of the deadliest cancers, the agency said Wednesday. Researchers have called the drug, known as Rasonque or daraxonrasib, a “landmark” development. In a trial of 5...

Redirecting to full article...